Patents by Inventor Martin Bossart

Martin Bossart has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SELECTIVE GIP RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING AND THERAPY PURPOSES
    Publication number: 20230127047
    Abstract: The present invention relates to GIP(1-30) analogues which selectively bind and activate the GIP receptor and comprise a chelating moiety capable of binding a metal ion and their use, for example in PET imaging or for radiotherapy.
    Type: Application
    Filed: March 30, 2021
    Publication date: April 27, 2023
    Inventors: Andreas Evers, Michael Wagner, Torsten Haack, Martin Bossart, Katrin Lorenz
  • GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis
    Patent number: 11352405
    Abstract: The present invention relates to the medical use of specific GLP-1/glucagon receptor agonists in the prevention and/or treatment of metabolic liver disease, particularly non-alcoholic fatty liver disease (NAFLD), more particularly non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH) and/or NAFLD-associated liver fibrosis.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: June 7, 2022
    Assignee: SANOFI
    Inventors: Aimo Kannt, Maximilian Bielohuby, Ralf Elvert, Michael Wagner, Martin Bossart, Torsten Haack, Stephanie Keil, Werner Seiz
  • Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic acid
    Patent number: 11141489
    Abstract: The present invention relates to a conjugate or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon receptor agonist, a linker and a hyaluronic acid hydrogel bearing -L1-L2-L-L-Y—R20 groups, wherein Y represents an GLP-1/Glucagon receptor agonist moiety; and -L is a linker moiety—by formula (Ia), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon receptor agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising the conjugate or the pharmaceutically acceptable salt thereof as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon receptor agonist.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: October 12, 2021
    Assignee: SANOFI
    Inventors: Dieter Kadereit, Michael Wagner, Thomas Olpp, Nino Meyer, Martin Bossart, Andreas Evers, Peyman Sakhaii, Pradeep K. Dhal, Paul Konowicz, James E. Stefano, Nils Poth
  • Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes
    Patent number: 11046743
    Abstract: The present invention relates to exendin-4 peptide analogues which selectively bind and activate the glucagon receptor and comprise a chelating moiety capable of binding a metal ion and their use, for example in PET imaging.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: June 29, 2021
    Assignee: ANTAROS MEDICAL AB
    Inventors: Torsten Haack, Oliver Plettenburg, Andreas Evers, Michael Wagner, Martin Bossart, Romain Bertrand
  • Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugate
    Patent number: 10806797
    Abstract: The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon agonist linker conjugate Z-L1-L2-L-Y—R20, wherein Y represents an GLP-1/Glucagon agonist moiety; and -L is a linker moiety—by formula (Ia), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said prodrugs as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon agonist.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: October 20, 2020
    Assignee: SANOFI
    Inventors: Dieter Kadereit, Michael Wagner, Thomas Olpp, Nino Meyer, Pradeep Dhal, Paul Konowicz, Robert Miller, James Stefano, Magnus Besev, Martin Bossart, Katrin Lorenz, Torsten Haack, Andreas Evers
  • Conjugates comprising an GLP-1/glucagon dual agonist, a linker and hyaluronic acid
    Patent number: 10792367
    Abstract: The present invention relates to a conjugate or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon receptor agonist, a linker and a hyaluronic acid hydrogel bearing -L1-L2-L-Y—R20 groups, wherein Y represents an GLP-1/Glucagon receptor agonist moiety; and -L is a linker moiety—by formula (Ia), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon receptor agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising the conjugates as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon receptor agonist.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: October 6, 2020
    Assignee: SANOFI
    Inventors: Dieter Kadereit, Michael Wagner, Thomas Olpp, Nino Meyer, Martin Bossart, Andreas Evers, Peyman Sakhaii, Pradeep K. Dhal, Paul Konowicz, James E. Stefano, Nils Poth
  • Exendin-4 derivatives as dual GLP1/glucagon agonists
    Patent number: 10758592
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: September 1, 2020
    Assignee: SANOFI
    Inventors: Torsten Haack, Michael Wagner, Bernd Henkel, Siegfried Stengelin, Andreas Evers, Martin Bossart
  • SELECTIVE GLUCAGON RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING PURPOSES
    Publication number: 20200262885
    Abstract: The present invention relates to exendin-4 peptide analogues which selectively bind and activate the glucagon receptor and comprise a chelating moiety capable of binding a metal ion and their use, for example in PET imaging.
    Type: Application
    Filed: December 12, 2016
    Publication date: August 20, 2020
    Inventors: Torsten HAACK, Oliver PLETTENBURG, Andreas EVERS, Michael WAGNER, Martin BOSSART, Romain BETRAND
  • GLP-1/GLUCAGON RECEPTOR AGONISTS IN THE TREATMENT OF FATTY LIVER DISEASE AND STEATOHEPATITIS
    Publication number: 20200216510
    Abstract: The present invention relates to the medical use of specific GLP-1/glucagon receptor agonists in the prevention and/or treatment of metabolic liver disease, particularly non-alcoholic fatty liver disease (NAFLD), more particularly non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH) and/or NAFLD-associated liver fibrosis.
    Type: Application
    Filed: August 8, 2018
    Publication date: July 9, 2020
    Inventors: Aimo KANNT, Maximilian BIELOHUBY, Ralf ELVERT, Michael WAGNER, Martin BOSSART, Torsten HAACK, Stephanie KEIL, Werner SEIZ
  • CONJUGATES COMPRISING AN GLP-1/GLUCAGON DUAL AGONIST, A LINKER AND HYALURONIC ACID
    Publication number: 20200155688
    Abstract: The present invention relates to a conjugate or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon receptor agonist, a linker and a hyaluronic acid hydrogel bearing -L1-L2-L-Y—R20 groups, wherein Y represents an GLP-1/Glucagon receptor agonist moiety; and -L is a linker moiety—by formula (Ia), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon receptor agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said conjugates as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon receptor agonist.
    Type: Application
    Filed: October 28, 2019
    Publication date: May 21, 2020
    Inventors: Dieter KADEREIT, Michael WAGNER, Thomas OLPP, Nino MEYER, Martin BOSSART, Andreas EVERS, Peyman SAKHAII, Pradeep K. DHAL, Paul KONOWICZ, James E. STEFANO, Nils POTH
  • Compounds as peptidic trigonal GLP1/glucagon/GIP receptor agonists
    Patent number: 10538567
    Abstract: The present invention relates to trigonal GLP-1/glucagon/GIP receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: January 21, 2020
    Assignee: SANOFI
    Inventors: Martin Bossart, Andreas Evers, Torsten Haack, Dieter Kadereit, Katrin Lorenz, Michael Wagner, Stefania Pfeiffer-Marek, Martin Lorenz
  • Compounds as peptidic GLP1/glucagon/GIP receptor agonists
    Patent number: 10519211
    Abstract: The present invention relates to trigonal GLP-1/glucagon/GIP receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: December 31, 2019
    Assignee: SANOFI
    Inventors: Martin Bossart, Andreas Evers, Torsten Haack, Katrin Lorenz, Dieter Kadereit, Michael Wagner, Stefania Pfeiffer-Marek, Martin Lorenz
  • PRODRUGS COMPRISING AN GLP-1/GLUCAGON DUAL AGONIST LINKER HYALURONIC ACID CONJUGATE
    Publication number: 20180289822
    Abstract: The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon agonist linker conjugate Z-L1-L2-L-Y—R20, wherein Y represents an GLP-1/Glucagon agonist moiety; and -L is a linker moiety—by formula (Ia), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said prodrugs as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon agonist.
    Type: Application
    Filed: June 2, 2016
    Publication date: October 11, 2018
    Inventors: Dieter KADEREIT, Michael WAGNER, Thomas OLPP, Nino MEYER, Pradeep DHAL, Paul KONOWICZ, Robert MILLER, James STEFANO, Magnus BESEV, Martin BOSSART, Katrin LORENZ, Torsten HAACK, Andreas EVERS
  • EXENDIN-4 DERIVATIVES AS DUAL GLP1/GLUCAGON AGONISTS
    Publication number: 20180185450
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
    Type: Application
    Filed: December 11, 2017
    Publication date: July 5, 2018
    Inventors: Torsten Haack, Michael Wagner, Bernd Henkel, Siegfried Stengelin, Andreas Evers, Martin Bossart
  • COMPOUNDS AS PEPTIDIC TRIGONAL GLP1/GLUCAGON/GIP RECEPTOR AGONISTS
    Publication number: 20180155406
    Abstract: The present invention relates to trigonal GLP-1/glucagon/GIP receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.
    Type: Application
    Filed: December 1, 2017
    Publication date: June 7, 2018
    Inventors: Martin BOSSART, Andreas EVERS, Torsten HAACK, Dieter KADEREIT, Katrin LORENZ, Michael WAGNER, Stefania PFEIFFER-MAREK, Martin LORENZ
  • CONJUGATES COMPRISING AN GLP-1/GLUCAGON DUAL AGONIST, A LINKER AND HYALURONIC ACID
    Publication number: 20180154005
    Abstract: The present invention relates to a conjugate or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon receptor agonist, a linker and a hyaluronic acid hydrogel bearing -L1-L2-L-Y—R20 groups, wherein Y represents an GLP-1/Glucagon receptor agonist moiety; and -L is a linker moiety—by formula (la), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon receptor agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said conjugates as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon receptor agonist.
    Type: Application
    Filed: December 1, 2017
    Publication date: June 7, 2018
    Inventors: Dieter KADEREIT, Michael WAGNER, Thomas OLPP, Nino MEYER, Martin BOSSART, Andreas EVERS, Peyman SAKHAII, Pradeep K. DHAL, Paul KONOWICZ, James E. STEFANO
  • COMPOUNDS AS PEPTIDIC GLP1/GLUCAGON/GIP RECEPTOR AGONISTS
    Publication number: 20180155407
    Abstract: The present invention relates to trigonal GLP-1/glucagon/GIP receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.
    Type: Application
    Filed: December 1, 2017
    Publication date: June 7, 2018
    Inventors: Martin BOSSART, Andreas EVERS, Torsten HAACK, Katrin LORENZ, Dieter KADEREIT, Michael WAGNER, Stefania PFEIFFER-MAREK, Martin LORENZ
  • Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
    Patent number: 9982029
    Abstract: The present invention relates to dual GLP-1/glucagon receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: May 29, 2018
    Assignee: SANOFI
    Inventors: Martin Bossart, Andreas Evers, Torsten Haack, Katrin Lorenz, Dieter Kadereit, Michael Wagner, Bernd Henkel
  • Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
    Patent number: 9775904
    Abstract: The present invention relates to dual GLP-1/glucagon receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: October 3, 2017
    Assignee: SANOFI
    Inventors: Martin Bossart, Ralf Elvert, Andreas Evers, Torsten Haack, Siegfried Stengelin, Michael Wagner
  • Peptidic dual GLP-1/glucagon receptor agonists derived from exendin-4
    Patent number: 9771406
    Abstract: The present invention relates to dual GLP-1/glucagon receptor agonists or optionally trigonal GLP-1/glucagon/GIP receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: September 26, 2017
    Assignee: SANOFI
    Inventors: Martin Bossart, Ralf Elvert, Andreas Evers, Torsten Haack, Siegfried Stengelin, Michael Wagner, Katrin Lorenz